In recent years, the indications for transcatheter aortic valve replacement (TAVR) have expanded from inoperable and high risk surgical patients to encompass patients at intermediate and low operative risk [ , ]. The evolution of transcatheter techniques is ongoing, with the development of improved new-generation devices and reduced profile delivery systems. This, together with increased operator experience, has led to significant improvements in the safety and efficacy of TAVR. As a result, we have witnessed exponential growth in the number of TAVR procedures performed, which is predicted to continue into the future [ ]. This has a substantial impact on increasing the economic costs, necessitating equally important advancements in health care resource planning.